141 results
Page 4 of 8
8-K
EX-99.1
m1sz7alrlg a9kb
28 Oct 13
BioTime Organizes New ESI BIO Division to Develop, Manufacture and Market the Company’s Cell-Based Research Products
12:00am
8-K
EX-99.1
u47bfo083uf2kf
28 Oct 13
BioTime Reports Interim Results on Renevia™ Clinical Safety Trial
12:00am
8-K
EX-99.1
votl1 oc81k
4 Oct 13
BioTime Announces Additional Products in Development Based on HyStem® Technology
12:00am
8-K
EX-99.1
64184dhmdtv0fda7
1 Oct 13
Asterias Biotherapeutics, Inc., a Subsidiary of BioTime, Inc., Acquires Geron’s Embryonic Stem Cell Assets
12:00am
8-K
EX-99.1
74o7s20j3cg8hspbap
19 Sep 13
BioTime Signs Exclusive Agreement with Jade Therapeutics for Ophthalmic Drug Delivery Applications of HyStem® Technology
12:00am
8-K
EX-99.1
h5az8rf
28 Aug 13
BioTime Receives Approval to Begin Human Clinical Trials of Renevia
12:00am
8-K
EX-99.1
gp6ysx3pmvsxjomixd8
21 Aug 13
BioTime Announces the Appointment of Lesley Stolz as Executive Vice President of Corporate Development
12:00am
8-K
EX-99.1
hnyjeov
5 Aug 13
BioTime’s Subsidiary OncoCyte Corporation Publishes Data on the Gene FSIP1 as a Breast Cancer-Specific Marker
12:00am
424B3
t4umi
2 Aug 13
Prospectus supplement
12:00am
8-K
EX-99.1
ko5g76hkdr59wxgj6
16 Jul 13
BioTime CEO Dr. Michael West to Present at the Case Western Reserve University 6th Annual Regenerative Medicine Business Education Course
12:00am
8-K
EX-99.1
0p85mzrmdot
12 Jun 13
BioTime Appoints Henry L. Nordhoff to Board of Directors
12:00am
8-K
EX-99.1
o3130jq0ua7qs
7 Jun 13
BioTime, Inc. Closes on $9 Million Financing
12:00am
424B5
cq6qvprrmr
3 Jun 13
Prospectus supplement for primary offering
12:00am
8-K
EX-99.1
ewnz4l5xzvvdbyr5d0
3 Jun 13
BioTime, Inc. to Raise $9 Million in Registered Direct Offering
12:00am
8-K
EX-99.1
oe2cnorz7ko7bz q2j
23 May 13
BioTime Announces Results of Vote at Special Meeting of Shareholders
12:00am
8-K
EX-99.1
1k7y556v z87z
30 Apr 13
BioTime Announces CFO Succession Plan
12:00am